Home

Direktor Erschreckend Brunnen puma biotech Rhythmisch Verzweiflung Glücksspiel

Takeda farms out cancer drug alisertib to Puma Biotech -
Takeda farms out cancer drug alisertib to Puma Biotech -

Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology Announces $10 Million Private Placement | Business Wire

Exhibitor Puma Biotechnology 02-20 - Scripps CME Connection
Exhibitor Puma Biotechnology 02-20 - Scripps CME Connection

PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence

Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) |  Seeking Alpha
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha

Puma Biotechnology Inc
Puma Biotechnology Inc

Puma Biotech Gets $100M Loan to Boost Breast Cancer Drug - Los Angeles  Business Journal
Puma Biotech Gets $100M Loan to Boost Breast Cancer Drug - Los Angeles Business Journal

Puma Biotechnology
Puma Biotechnology

Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology Announces $10 Million Private Placement | Business Wire

Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital |  Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire

Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib

Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital |  citybiz
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz

Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat

Is Puma Biotechnology a Buy? | The Motley Fool
Is Puma Biotechnology a Buy? | The Motley Fool

Puma Biotechnology
Puma Biotechnology

Puma Biotechnology
Puma Biotechnology

Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors  think so | Fierce Pharma
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma

PumaBiotech (@pumabiotech) / Twitter
PumaBiotech (@pumabiotech) / Twitter

SEC charges former Puma biotech exec with $1.1 million in insider trading
SEC charges former Puma biotech exec with $1.1 million in insider trading

Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital |  Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire

Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing  Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business  Wire
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire

Former Puma Biotech executive gets U.S. prison term for insider trading |  Reuters.com
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com

Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in  China - Los Angeles Business Journal
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal

Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet

Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha

PumaBiotech (@pumabiotech) / Twitter
PumaBiotech (@pumabiotech) / Twitter